Research

Hormonal

GLP-1 RAs are not associated with progression to proliferative diabetic retinopathy (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) in patients with preexisting DR.

Patients with preexisting DR may not experience worsening of certain complications when treated with GLP-1 RAs.

StrongRefutesmedium confidence
GLP-1 RAs were not associated with progression to proliferative DR (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01).
David J. Ramsey et al. · JAMA Network Open · 2025

Why this rating

Based on a large retrospective cohort study design.

Source

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes

David J. Ramsey et al. · JAMA Network Open · 2025

DOI 10.1001/jamanetworkopen.2025.26321

cohort · n=185066Cited 41×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →